Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Outlook Therapeutics has submitted an application to the Centers for Medicare & Medicaid Services (CMS) requesting a permanent, product-specific HCPCS Level II J-code for its FDA-approved ophthalmic drug LYTENAVA, used in treating wet age-related macular degeneration (wet AMD). The move aims to facilitate reimbursement, streamline billing, and enha…